Author contributions
Guillermo Hernández Silva: Studied the conception and designed the
study, also reviewed the manuscript.
Ricardo Giovanni Puerto Chaparro: Studied the conception and designed
the study, also reviewed the manuscript.
Javier Álvaro Martínez Melo: Studied the conception and designed the
study, also reviewed the manuscript.
Cristian Orlando Porras Bueno: Wrote, reviewed the manuscript and also
was involved in acquisition of data and analysis of data.
Javier Eduardo Martínez Rodríguez: Wrote, reviewed the manuscript and
also was involved in acquisition of data and analysis of data.
Sharon Julieth González Trillos: Wrote, reviewed the manuscript and also
was involved in acquisition of data and analysis of data.
References
1. Stolp J, Zaitsu M, Wood KJ. Immune Tolerance and Rejection
in Organ Transplantation. Methods Mol Biol. 2019; 1899:159-180.
2. Noble J, Terrec F, Malvezzi P, Rostaing L. Adverse effects
of immunosuppression after liver transplantation. Best Pract Res Clin
Gastroenterol. 2021;54-55:101762. doi: 10.1016/j.bpg.2021.101762
3. Farouk SS, Rein JL. The Many Faces of Calcineurin Inhibitor
Toxicity-What the FK?. Adv Chronic Kidney Dis. 2020;27(1):56-66. doi:
10.1053/j.ackd.2019.08.006
4. Robert N, Wong GW, Wright JM. Effect of cyclosporine on
blood pressure. Cochrane Database Syst Rev. 2010;(1):CD007893. Published
2010 Jan 20. doi: 10.1002/14651858.CD007893.pub2
5. Nakata Y, Yoshibayashi M, Yonemura T, et al. Tacrolimus and
myocardial hypertrophy. Transplantation. 2000;69(9):1960-1962.
doi:10.1097/00007890-200005150-00039
6. Bowman LJ, Brennan DC, Delos-Santos R, Larue SJ, Anwar S,
Klein CL. Tacrolimus-induced cardiomyopathy in an adult renal transplant
recipient. Pharmacotherapy. 2015;35(12):1109-1116. doi:10.1002/phar.1666
7. Dehghani SM, Haghighat M, Imanieh MH, et al. Tacrolimus
related hypertrophic cardiomyopathy in liver transplant recipients. Arch
Iran Med. 2010;13(2):116-119.
8. Liu T, Gao Y, Gao YL, et al. Tacrolimus-related hypertrophic
cardiomyopathy in an adult cardiac transplant patient. Chin Med J
(Engl). 2012;125(7):1352-1354.
9. Atkison P, Joubert G, Barron A, et al. Hypertrophic
cardiomyopathy associated with tacrolimus in paediatric transplant
patients. Lancet. 1995;345(8954):894-896.
doi:10.1016/s0140-6736(95)90011-x
10. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D,
Arnett D, et al. Contemporary definitions and classification of the
cardiomyopathies: An American Heart Association Scientific Statement
from the Council on Clinical Cardiology, Heart Failure and
Transplantation Committee; Quality of Care and Outcomes Research and
Functional Genomics and Translational Biology Interdisciplinary Working
Groups; and Council on Epidemiology and Prevention. Circulation.
2006;113(14):1807–16.
11. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F,
Charron P, et al. Classification of the cardiomyopathies: A position
statement from the european society of cardiology working group on
myocardial and pericardial diseases. Eur Heart J. 2008;29(2):270–6.
12. Atkison P, Joubert G, Barron A, et al. Hypertrophic
cardiomyopathy associated with tacrolimus in paediatric transplant
patients. Lancet. 1995;345(8954):894-896.
doi:10.1016/s0140-6736(95)90011-x
13. Noda K, Ukichi T, Furuya K, et al. Tacrolimus-induced
hypertrophic cardiomyopathy in a patient with dermatomyositis.
Rheumatology (Oxford). 2017;56(11):2037-2038.
doi:10.1093/rheumatology/kex310
14. Bowman LJ, Brennan DC, Delos-Santos R, LaRue SJ, Anwar S,
Klein CL. Tacrolimus-Induced Cardiomyopathy in an Adult Renal Transplant
Recipient. Pharmacotherapy. 2015;35(12):1109-1116. doi:10.1002/phar.1666
15. Turska-Kmieć A, Jankowska I, Pawłowska J, et al. Reversal
of tacrolimus-related hypertrophic cardiomyopathy after conversion to
rapamycin in a pediatric liver transplant recipient. Pediatr Transplant.
2007;11(3):319-323. doi:10.1111/j.1399-3046.2006.00633.x
16. Méndez-Abad P, Zafra-Rodríguez P. Miocardiopatía
hipertrófica en un recién nacido pretérmino con madre trasplantada renal
[Hypertrophic cardiomyopathy in preterm newborn with kidney
transplanted mother]. Arch Argent Pediatr. 2018;116(6):e749-e752.
doi:10.5546/aap.2018.e749
17. Jarzembowski TM, John E, Panaro F, et al. Reversal of
tacrolimus-related hypertrophic obstructive cardiomyopathy 5 years after
kidney transplant in a 6-year-old recipient. Pediatr Transplant.
2005;9(1):117-121. doi:10.1111/j.1399-3046.2005.00260.x
18. Chang RK, McDiarmid SV, Alejos JC, Drant SE, Klitzner TS.
Echocardiographic findings of hypertrophic cardiomyopathy in children
after orthotopic liver transplantation. Pediatr Transplant.
2001;5(3):187-191. doi:10.1034/j.1399-3046.2001.00052.x
19. Kakhi S, Phanish MK, Anderson L. Dilated Cardiomyopathy in
an Adult Renal Transplant Recipient: Recovery Upon Tacrolimus to
Sirolimus Switch: A Case Report. Transplant Proc. 2020;52(9):2758-2761.
doi:10.1016/j.transproceed.2020.06.011
20. McLeod J, Wu S, Grazette L, Sarcon A. Tacrolimus-Associated
Dilated Cardiomyopathy in Adult Patient After Orthotopic Liver
Transplant. J Investig Med High Impact Case Rep.
2017;5(2):2324709617706087. Published 2017 Apr 27.
doi:10.1177/2324709617706087
21. Kakhi S, Phanish MK, Anderson L. Dilated Cardiomyopathy in
an Adult Renal Transplant Recipient: Recovery Upon Tacrolimus to
Sirolimus Switch: A Case Report. Transplant Proc. 2020;52(9):2758-2761.
doi:10.1016/j.transproceed.2020.06.011
22 . Pappas PA, Weppler D, Pinna AD, et al. Sirolimus in
pediatric gastrointestinal transplantation: the use of sirolimus for
pediatric transplant patients with tacrolimus-related cardiomyopathy.
Pediatr Transplant. 2000;4(1):45-49.
doi:10.1034/j.1399-3046.2000.00083.x